Pfizer

United States

1 Trial

Pfizer is a multinational pharmaceutical corporation that, through Pfizer Canada and the Canadian Pain Society, co-funded the KetHead multi-center Phase 3 RCT (NCT05306899) evaluating high-dose IV ketamine for chronic daily headaches at Toronto Western Hospital and Sinai Health System. The trial targets NMDA receptor-mediated central sensitization underlying refractory headache disorders.